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Abstract
Background: Neuroblastoma accounts for 7% of paediatric malignancies but is responsible for 15% of all childhood
cancer deaths. Despite rigorous treatment involving chemotherapy, surgery, radiotherapy and immunotherapy, the
5-year overall survival rate of high-risk disease remains < 40%, highlighting the need for improved therapy. Since
neuroblastoma cells exhibit aberrant metabolism, we determined whether their sensitivity to radiotherapy could be
enhanced by drugs affecting cancer cell metabolism.
Methods: Using a panel of neuroblastoma and glioma cells, we determined the radiosensitising effects of inhibitors
of glycolysis (2-DG) and mitochondrial function (metformin). Mechanisms underlying radiosensitisation were
determined by metabolomic and bioenergetic profiling, flow cytometry and live cell imaging and by evaluating
different treatment schedules.
Results: The radiosensitising effects of 2-DG were greatly enhanced by combination with the antidiabetic
biguanide, metformin. Metabolomic analysis and cellular bioenergetic profiling revealed this combination to elicit
severe disruption of key glycolytic and mitochondrial metabolites, causing significant reductions in ATP generation
and enhancing radiosensitivity. Combination treatment induced G2/M arrest that persisted for at least 24 h post-
irradiation, promoting apoptotic cell death in a large proportion of cells.
Conclusion: Our findings demonstrate that the radiosensitising effect of 2-DG was significantly enhanced by its
combination with metformin. This clearly demonstrates that dual metabolic targeting has potential to improve
clinical outcomes in children with high-risk neuroblastoma by overcoming radioresistance.
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Background
Neuroblastoma comprises 7% of paediatric malignancies
but has a worse prognosis than many other tumour
types, accounting for approximately 15% of childhood
cancer deaths [1]. Age at diagnosis, along with stage and
molecular characteristics of the tumour, is used to allo-
cate patients to low-intermediate- or high-risk groups.
Younger age, low stage, and absence of segmental
chromosomal abnormalities or oncogenic MYCN ampli-
fication are favourable features. However, most patients
have high-risk disease by virtue of age greater than 12
months and distant metastatic disease or MYCN amplifi-
cation [2]. The standard treatment schedule for high-
risk neuroblastoma involves a complex multimodality
schedule comprising induction chemotherapy [3],
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surgery [4], high-dose chemotherapy [5], radiotherapy
[6] and immunotherapy [7]. While some patients re-
spond well, some are refractory to initial treatments or
relapse later. As neuroblastoma arises from primordial
neural crest cells, most commonly in the adrenal me-
dulla and also at other sites in the sympathetic nervous
system, neuroblastoma cells usually retain the ability to
take up catecholamines and analogues such as meta-
iodobenzylguanidine (MIBG) [8]. Imaging with 123I-
MIBG is used for staging and response assessment, and
131I-MIBG is a valuable treatment option [9].
The prognosis for patients with high-risk neuroblast-
oma has undoubtedly improved significantly over recent
decades due to international cooperative group phase III
trials investigating intensification of treatments such as
high-dose chemotherapy and immunotherapy. Different
sources yield different survival rates depending on the
era of presentation, clinical trial selection factors, treat-
ments used, and follow-up duration. Ten-year overall
survival rates remain in the order of only 40% [10, 11],
and while newer approaches offer the prospect of im-
provements in long-term survival, follow-up durations
are currently insufficient to confirm these hopes [12].
Although 131I-MIBG is useful in the treatment of refrac-
tory and relapsed high-risk neuroblastoma and is the
subject of clinical trials (ClinicalTrials.gov identifiers
NCT02035137 and NCT03165292) aiming to optimise
its use, further strategies are required to ensure that
maximal benefit is obtained [13, 14]. It is likely that
maximal therapeutic benefit from targeted radiotherapy
will be obtained by its combination with drugs [14],
which might render it more effective specifically for
high-risk neuroblastoma patients, who do not benefit
from existing therapies.
In recent years, a growing body of evidence has emerged
demonstrating the anticancer properties of drugs that
modulate cellular metabolism. Aberrant mitochondrial
metabolism is a common trait among cancers. This is ex-
emplified by the Warburg effect, which is characterised by
increased rates of glycolysis and lactate production, even
in the presence of oxygen [15]. Dysregulated cancer cell
metabolism has been linked to increased tumour aggres-
siveness and treatment resistance [16]. Indeed, targeting
glucose metabolism has yielded chemo- and radiosensiti-
sation in several cancer types [17, 18]. Of relevance to this
study, neuroblastoma cells have been reported to exhibit
aberrant metabolic properties, including increased fatty
acid synthase expression [19] and altered fatty acid and
glucose metabolism [20].
The synthetic glucose analogue 2-deoxyglucose (2-DG)
is avidly taken up by rapidly proliferating cells, including
cancer cells. Once internalised, 2-DG is unable to undergo
isomerisation at its second carbon atom to produce 2-
deoxyglucose-6-phosphate, a phenomenon that leads to
inhibition of glycolysis at the phosphoglucoisomerase
level. Therefore, treatment with 2-DG becomes cytotoxic
in the contexts of ATP depletion [21] or disruption of
glutathione metabolism [22]. In keeping with this, 2-DG
was shown to be an effective radiosensitiser of HeLa cells
[22] and was well tolerated in combination with docetaxel
in a phase 1, dose-escalation clinical trial [23].
Metformin is a biguanide drug that is widely pre-
scribed for the treatment of type 2 diabetes, acting to re-
duce insulin resistance, enhance glucose utilisation and
reduce hepatic glucose production [24]. At the cellular
level, metformin promotes AMPK activation during en-
ergy homeostasis via inhibition of Complex I of the
mitochondrial respiratory chain [25, 26]. Indeed, metfor-
min has been shown to exhibit antineoplastic activity in
the context of exogenously induced changes in energy
homeostasis [27]. Additionally, patients with type 2 dia-
betes who were receiving metformin as part of their dia-
betic management have been shown to experience
reduced incidence and better survival rates for many
solid cancers [28–30].
In keeping with these observations, both 2-DG and
metformin have shown potential as radio- [22, 31–34]
and chemosensitisers [23, 35, 36]. However, their abil-
ity to sensitise neuroblastoma cells to radiotherapy
has not yet been studied, and the mechanisms under-
lying their radiosensitising properties are poorly
understood. Accordingly, we investigated the potential
of 2-DG and metformin to enhance the efficacy of X-
irradiation in pre-clinical models of neuroblastoma.
We show that 2-DG effectively radiosensitises neuro-
blastoma and glioma cells, effects that are significantly
enhanced in the presence of metformin, and demon-
strate that combining 2-DG, metformin and radiation
induces extensive metabolic reprogramming. This is
characterised by reduced cellular respiration and ATP
production that associates with prolonged G2/M ar-
rest during which cells ultimately succumb to apop-
totic cell death. Our results indicate that dual
pharmacological inhibition of glycolysis and mito-
chondrial respiration has potential to enhance the ef-




2-Deoxy-D-glucose (2DG; D3179) and metformin hydro-
chloride (PHR1084) were purchased from Sigma-Aldrich
(Poole, UK) and were reconstituted using sterile water.
Drugs were then diluted in culture medium. Unless other-
wise stated, all other cell culture reagents were purchased
from Thermo Fisher Scientific (Paisley, UK) and all che-
micals were purchased from Sigma-Aldrich (Poole, UK).
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Cell culture
Human neuroblastoma SK-N-BE(2c) cells were pur-
chased from the American Type Culture Collection and
were maintained in Dulbecco’s modified Eagle medium
(DMEM) containing 15% (v/v) fetal calf serum, 2 mM L-
glutamine and 1% (v/v) non-essential amino acids. Hu-
man glioblastoma UVW cells were transfected with a
plasmid containing the bovine noradrenaline transporter
(NAT) gene [37] and were maintained in minimum es-
sential medium (MEM) containing 10% (v/v) fetal calf
serum, 2 mM L-glutamine, 1% (v/v) non-essential amino
acids and 1 mg/ml geneticin. Human neuroblastoma
CHLA-20 cells were obtained from the Children’s On-
cology Group Childhood Cancer Repository (TX, USA)
and were maintained in Iscove’s modified Dulbecco’s
medium (IMDM) containing 20% (v/v) fetal calf serum,
2 mM L-glutamine and 1% (v/v) insulin-transferrin-
selenium. All cells were incubated at 37 °C, 5% CO2 in a
humidified incubator, and were passaged every 3–4 days.
Cell lines were cultured in this study for less than 6
months after resuscitation and were deemed free of
Mycoplasma contamination by in-house testing using
the MycoAlert mycoplasma detection kit (Lonza, Bazel,
Switzerland).
MTT cell growth assay
The MTT reduction assay was used to estimate the effect
of drug treatment on cell growth up to 96 h post treat-
ment. After seeding cells in 96-well plates, the following
day, cells were washed with PBS before adding 200 μl
drug-containing medium. After 24 h, 48 h, 72 h, and 96 h,
cells were incubated for 2 h with 20 μl MTT solution (5
mg/ml MTT in PBS). Internalised MTT was solubilised
with DMSO and absorbance was measured at 570 nm.
Clonogenic assay
Monolayers were cultured in 25 cm2 flasks before 24-h
drug treatment and simultaneous irradiation (Xstrahl
RS225 X-Ray irradiator, Xstrahl Limited, Surrey, UK;
dose rate of 0.93 Gy/min) at the stated concentrations
and doses. Irradiation was always administered at the be-
ginning of drug treatment, with the only exception being
during the alternative scheduling experiments (as further
detailed in the text). Clonogenic survival was determined
by seeding 500 (SK-N-BE(2c)) or 250 (UVW/NAT) cells
in to 21.5 cm2 petri dishes as previously described [38].
Spheroid growth delay
Cells were cultured in 25 cm2 flasks coated with 1% (w/
v) agar to initiate multicellular spheroid formation. After
3 days, spheroids were transferred to sterile universal
tubes before treatment in serum-free drug-containing
medium and simultaneous irradiation. Spheroids were
treated for 24 h, and those of approximately 100 μm in
diameter were individually transferred to agar-coated
24-well plates, with 12 replicate spheroids per condition,
as previously described [39, 40]. Each spheroid was im-
aged every 3–4 days for 3 weeks using an inverted phase
contrast microscope. The longest spheroid length, dmax,
and its perpendicular width, dmin, were measured using
ImageJ (NIH, Bethesda, MD). Tumour volume, V (μm3)
was then estimated assuming V = π × dmax × dmin
2/6
[41], which allowed determination of the area under the
V/V0 versus time curve (AUC) using trapezoidal ap-
proximation [39, 40].
Untargeted metabolomic analysis
Hydrophilic interaction liquid chromatography (HILIC)
was carried out on a Dionex UltiMate 3000 RSLC sys-
tem (Thermo Fisher Scientific, Hemel Hempstead, UK)
using a ZIC-pHILIC column (150 mm × 4.6 mm, 5-μm
column, Merck Sequant). The column was maintained
at 30 °C and samples were eluted with a linear gradient
(20 mM ammonium carbonate in water and acetonitrile)
over 26 min at a flow rate of 0.3 ml/min. The injection
volume was 10 μl and samples were maintained at 5 °C
prior to injection. Metabolites were detected using the
Thermo Orbitrap Q Exactive (Thermo Fisher Scientific)
mass spectrometer at a resolution of 70,000 (at 70–1050
m/z), which was operated in polarity switching mode. A
pooled sample comprising a mixture of all sample ex-
tracts was analysed using the same conditions and was
run every 5th sample. Instrument .raw files were con-
verted to positive and negative ionisation mode mzXML
files. These files were then analysed using the XCMS
[42]/MZMatch [43]/IDEOM pipeline. Polyomics inte-
grated Metabolomics Pipeline (PiMP) and FrAnK were
used to assess fragmentation data [44]. The weighted
distance of treatment conditions to untreated control
samples was calculated using the following equation:
Weighted distance ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðPC1 repn−PC1 Ctrlmeanð Þ  0:49Þ2 þ PC2 repn−PC1 Ctrlmeanð Þ  0:218ð Þ2
q
where PC1repn is the PC1 value of each replicate and
PC1Ctrlmean is the mean PC1 value of all untreated con-
trol samples [45]. All metabolomic data has been
uploaded to the repository MetaboLights (https://www.
ebi.ac.uk/metabolights/).
Bioenergetic analysis of glycolysis and mitochondrial
respiration
UVW/NAT cells and CHLA-20 cells were seeded at a
density of 1 × 104 and 3 × 104 cells, respectively, in a
volume of 175 μl in Seahorse XFe96-well plates (Cat#
101085-004, Seahorse Biosciences, Agilent Technologies,
Cheshire, UK). Cells were allowed to settle for 2 h at
room temperature, before drug treatment (25 μl) and
simultaneous irradiation, as required. Mitochondrial
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respiration was measured 24 h after treatment using the
Seahorse XFe96 Analyzer (Seahorse Biosciences, Agilent
Technologies, Cheshire, UK) according to manufac-
turer’s instructions. On the day of the assay, culture
medium was replaced with Seahorse XF base medium
(Cat# 102353-100), supplemented with the regents re-
quired for each cell line (except FBS), as detailed above.
Cells were then incubated for 1 h at 37 °C in the absence
of CO2. Using the Seahorse Cell Mito Stress Test (Cat#
103015-100), sequential injections were made of oligo-
mycin (1 μM), carbonyl cyanide-p-trifluoromethoxy-
phenylhydrazone (FCCP) (1 μM), rotenone (0.5 μM) and
antimycin A (0.5 μM) to test cellular response to mito-
chondrial stress in live cells. Mitochondrial oxygen con-
sumption rate (OCR) and extracellular acidification rate
(ECAR) were measured every 3 min, for a total of 75
min. The OCR and ECAR traces were then used to esti-
mate basal and maximal respiration, ATP synthesis, and
glycolytic rate as described previously [46]. Data were
normalised to protein content, which was determined
after each Seahorse assay using the Pierce Micro BCA
Protein Assay kit (Cat# 23235, Thermo Fisher Scientific,
Paisley, UK), following manufacturer’s instructions.
Fluorescence-activated cell sorting (FACS) analysis
Cells were seeded at a density of 7 × 105 (SK-N-BE(2c))
or 4 × 105 (UVW/NAT) cells in 75 cm2 flasks. Drug-
containing medium was added once cells were 60% con-
fluent, and cells were simultaneously irradiated. After 24
h, cells were trypsinised and washed with PBS, before
fixing with 70% (v/v) ethanol in water at − 20°C for a
minimum of 6 h. Ethanol was removed by washing with
PBS and cells were resuspended in PBS containing pro-
pidium iodide (10 μg/ml) and RNase A (200 μg/ml), be-
fore analysis using a BD FACSVerse flow cytometer (BD
BioSciences, Oxford, UK). FACS data were quantified
using FlowJo 7.6.5 software. Our gating strategy is pro-
vided in Supplementary Information Fig. S8a.
Live cell imaging
For real-time analysis of cellular proliferation and apoptotic
frequency, UVW/NAT and CHLA20 cells were seeded in
96-well plates at densities of 1.5 × 103 or 1.75 × 104 cells/
well, respectively. After overnight incubation at 37 °C,
Annexin V-labelled cells (IncuCyte Annexin V Red, Cat#
4641, Essen BioScience, 1:400) were analysed with the Incu-
Cyte ZOOM live cell imaging system (Essen BioScience,
Hertfordshire, UK) following drug treatment (as detailed in
the text). Each condition was replicated in six wells per ex-
periment for each cell line. Two images per well were ac-
quired every hour at a magnification of × 10, over a time
period of 50 h. The number of Annexin V-positive cells
was normalised to total cell confluence, using the IncuCyte
ZOOM 2018A software (Ann Arbor, MI, USA).
Results
Radiosensitising effect of 2DG and metformin as single
agents
Both 2-DG and metformin exhibited modest activity as
single agents, with reductions in cell proliferation and clo-
nogenic survival being observed after exposure to concen-
trations greater than 1 mM 2DG or 10 mM metformin
(Supplementary Information Fig. S1a-d). When delivered
for 24 h commencing at the time of external beam radi-
ation, 2-DG reduced the clonogenic capacity of UVW/
NAT cells in a dose-dependent manner, with statistically
significant radiosensitisation observed at 5 mM and 10
mM, with dose enhancement factors at 50% cell kill
(DER50) of 1.80 and 1.69, respectively (Fig. 1a). Similarly,
10 mM 2-DG significantly enhanced X-irradiation in-
duced growth delay in SK-N-BE(2c)-derived spheroids,
with the combined effect being greater than either agent
administered alone (Fig. 1b). In contrast, metformin had
negligible effect on clonogenic survival of UVW/NAT
cells when administered in combination with irradiation
(Fig. 1c), results that were confirmed in SK-N-BE(2c) cells
(Supplementary Information Fig. S2).
Combined effects of 2-DG and metformin on
radiosensitisation
The failure of metformin to radiosensitise neuroblast-
oma and glioma cells contrasts with data from previous
studies on pancreatic [31] and breast cancer cells [34].
However, there is a rationale for combining metformin
treatment with 2-DG treatment. Inhibition of glycolysis
by 2-DG is predicted to cause a compensatory increase
in mitochondrial respiration to maintain ATP produc-
tion. Combination treatment with metformin would cir-
cumvent this compensatory increase in mitochondrial
metabolism by inhibiting Complex 1 of the respiratory
chain. There is also evidence of supra-additive activity of
2-DG and metformin combination treatment in other
cancer types [47–49]. Most pertinently, Chatterjee and
colleagues demonstrated that simultaneous administra-
tion of 2-DG and metformin enhanced radiation-
induced cytotoxicity in two breast cancer cell lines [50].
In keeping with this rationale, 2-DG and metformin
exerted additive effects on clonogenic cell kill in the ab-
sence of radiation (Supplementary Information Fig. S1e-
f). Likewise, dual treatment with low doses of 2-DG and
metformin (1 mM) significantly radiosensitised UVW/
NAT cells (drugs administered for 24 h commencing at
the time of irradiation, Fig. 2a) but failed to radiosensi-
tise SK-N-BE(2c) cells (Fig. 2b).
Since SK-N-BE(2c) cells exhibit a longer population
doubling time (37 h) than UVW/NAT cells (16 h), we
postulated that more prolonged drug treatment might
be required to radiosensitise these cells. However, 48h
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exposure to metformin and 2-DG also failed to increase
radiation-induced cell kill (Fig. 2b).
Because of the discrepancy between UVW/NAT glioma
cells and SK-N-BE(2c) neuroblastoma cells, we evaluated
an alternative human neuroblastoma cell line, CHLA-20.
These cells were unable to form the colonies required for
clonogenic assay but readily formed three-dimensional
spheroids. In this clinically relevant model, we observed
enhanced spheroid growth delay following triple combin-
ation therapy, as opposed to single agent modalities
(Fig. 2c).
Combination treatment significantly disrupts glycolysis,
mitochondrial respiration and nucleotide metabolism
To understand why metformin enhanced the radiosensi-
tising potential of 2-DG in UVW/NAT cells, we
(See figure on previous page.)
Fig. 1 Radiosensitising effect of 2DG and metformin as single agents. The clonogenic survival of UVW/NAT cells following 24-h treatment with a
1, 5, or 10 mM 2DG or c 1, 5, or 10 mM metformin in the presence 1–4 Gy X-radiation (administered at the beginning of drug treatment). The
50% inhibitory concentration (IC50) and the dose enhancement factor observed at the 50% kill level (DEF50) are shown. b Growth inhibition of SK-
N-BE(2c)-derived multicellular spheroids (n = 3) after 24-h treatment with 4 Gy X-radiation or 10 mM 2DG, as single agents or in combination.
Data expressed as percentage are under the volume-time curve (AUC) with representative spheroids shown after 21-day treatment, × 5
magnification. *p < 0.05, **p < 0.01 compared to untreated control cells. All data are mean ± SEM from 3 experimental repeats
Fig. 2 Combined effect of 2DG and metformin on radiosensitisation. The effect of 2DG and metformin on the radiation-induced cell kill of a
UVW/NAT (n = 3) cells after 24h drug treatment and b SK-N-BE(2c) cells after 24h (n = 4) or 48h (n = 2) drug treatment. c Growth inhibition of
CHLA20-derived multicellular spheroids (n = 3) after 24h treatment with 2 Gy X-radiation (at the beginning of treatment), 10 mM metformin, or 5
mM 2DG, as single agents or in combination. Data expressed as percentage are under the volume-time curve (AUC). Representative CHLA20-
derived spheroids are shown after 21-day treatment, × 5 magnification. Data are means ± SEM from the stated number of experimental repeats.
*p < 0.05, **p < 0.01, ***p < 0.001 compared to irradiated (IR) cells (a, b) or untreated control cells (c)
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interrogated the effect of single agent and combination
treatments on glycolytic and mitochondrial respiration
metabolites. An initial untargeted analysis using a princi-
pal component plot revealed that 2-DG induced signifi-
cant changes in the metabolomic composition of UVW/
NAT cells, whether administered as a single agent or in
combination (Fig. 3a). Further interrogation of glycolytic
pathway metabolites revealed 2-deoxyglucose phosphate
to be significantly increased in cells exposed to 2-DG
treatment, proving that 2-DG was internalised and phos-
phorylated by hexokinase (Fig. 3b). This phosphorylation
rendered 2-DG refractory to metabolism by glycolysis, as
shown by the reduction in glyceradehyde-3-phosphate,
phosphoenolpyruvate and pyruvate, the end-product of
glycolysis, in all treatments involving 2-DG (Fig. 3b and
Supplementary Information Fig. S3a).
Likewise, investigation of the tricarboxylic acid (TCA)
cycle (Supplementary Information Fig. S3c) revealed cit-
rate/isocitrate and malate to be significantly reduced fol-
lowing exposure to single agent or combination therapy
involving 2-DG (Fig. 3c). Single agent metformin treat-
ment also significantly reduced the relative abundancies
of these metabolites, demonstrating inhibition of Com-
plex 1 of the respiratory chain.
Our metabolomic analysis also revealed that 2-DG sin-
gle agent treatment promoted large-scale changes in
purine and pyrimidine metabolism. Specifically, we ob-
served a decreased abundance in 20 of 26 metabolites
detectable within the purine metabolic pathway (Supple-
mentary Information Fig. S4). Similarly, 2-DG promoted
a reduction in 11 of the 27 metabolites we detected
within the pyrimidine metabolic pathway (Supplemen-
tary Information Fig. S5). Comparable results were ob-
served after metformin single agent therapy, but to a
lesser extent (data not shown). Further analysis of com-
bination treatments revealed that dual 2-DG/metformin
and triple 2-DG/metformin/radiation combination ther-
apies significantly increased the abundance of ethanol-
amine phosphate and hypoxanthine (Fig. 3d; p < 0.001),
which are products of serine and adenine metabolism,
respectively. Interestingly, the increased abundance of
these two metabolites was only observed following com-
bination treatments.
Metabolite imbalance following therapeutic intervention
culminates in impaired cellular respiration
Having demonstrated marked disruption of glycolysis
and mitochondrial metabolism by our combination drug
treatment, we explored its effects on cellular respiration
and energy production. The mitochondrial respiratory
profile of UVW/NAT and CHLA-20 cells was analysed
using the Seahorse XF system, whereby live cells were
sequentially injected with different test compounds to
induce mitochondrial stress (Supplementary Fig. S6).
Initially, basal extracellular acidification rate (ECAR) was
plotted against mitochondrial oxygen consumption rate
(OCR) (Fig. 4a). While these bioenergetic profiles were un-
affected by irradiation (3 Gy), 2-DG treatment promoted
aerobic respiration, presumably in response to glycolytic in-
hibition, whereas metformin-treated cells became increas-
ingly glycolytic as mitochondrial respiration was inhibited
(Fig. 4a, b). The greatest shift in bioenergetics was seen fol-
lowing combination therapy involving 2-DG and metformin
in the presence or absence of radiation, with cells becoming
less energetic and more quiescent as the two central ATP
production pathways were inhibited. Interestingly, single
agent metformin produced the greatest shift in mitochon-
drial respiratory capacity, with no additional effect observed
when 2-DG or radiation were added (Fig. 4c). Single agent
2-DG treatment, however, significantly increased both the
respiratory capacity and ATP production of UVW/NAT
cells. Our hypothesis that this reflected increased utilisation
of more efficient mitochondrial ATP production was sup-
ported by the reversal of the effect that was observed when
metformin was added (with or without irradiation, Fig. 4c,
d). Comparably, combination treatment significantly re-
duced abundance of the metabolites AMP, ADP and ATP
(Supplementary Information Fig. S3d). Similar results were
obtained in CHLA-20 cells (Supplementary Fig. 7).
Taken together, these results demonstrate that 2-DG
and metformin treatment caused significant disruption
of glycolysis and/or the mitochondrial TCA cycle, which
culminated in significantly impaired cellular energy pro-
duction. However, this effect was not enhanced in the
presence of irradiation, even though both drugs were re-
quired to enhance radiosensitivity.
Triple combination therapy significantly prolongs G2/M
cell cycle arrest
To further understand the mechanisms underlying the effi-
cacy of triple combination therapy, effects on cell cycle pro-
gression were investigated using the gating strategy
presented in Supplementary Fig. S8a. Single agent 2-DG
treatment at doses of 2.5 mM and above caused accumula-
tion of cells in G2/M phase of the cell cycle after 6 h,
whereas metformin had negligible effect on the proportion
of G2/M phase cells at any dose (Supplementary Fig. S8b-
c). However, combined low-dose (1 mM) treatment with 2-
DG and metformin caused a marked G2/M arrest that was
observed 6 h after treatment and failed to resolve at 24 h
(Fig. 5a). Radiation alone (3 Gy) caused a temporary G2/M
arrest, as expected, but did not amplify cell cycle effects of
the drug combination (Fig. 5a).
Our previous studies have demonstrated the import-
ance of scheduling when combining treatment modal-
ities [39, 51], and we predicted that accumulation of
cells in G2/M phase of the cell cycle would increase ra-
diosensitivity [52] by doubling the amount of DNA
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susceptible to radiation damage in each cell. To investigate
this possibility, three different schedules were tested: (1)
three treatments simultaneously, (2) 2-DG and metformin
6 h prior to irradiation, and (3) irradiation 6 h prior to 2-
DG and metformin (Supplementary Fig. S8d). Cells were
harvested after a total treatment time of 24 h and analysed
by propidium iodide staining and flow cytometry (Fig. 5b)
or clonogenic assay (Fig. 5c), to determine effects on cell
cycle distribution and cell survival, respectively. The 6h
interval was selected because maximum G2/M arrest was
observed at this timepoint (Fig. 5a) [38].
Maximum G2/M arrest at 24 h was observed when
cells were irradiated 6 h prior to drug therapy (Schedule
3, Fig. 5b). Schedules 1 and 2 were less effective, yielding
2-fold increases in the proportion of cells in G2/M
phase. While all three combination schedules enhanced
clonogenic cell kill compared to individual treatments
(Fig. 5c), no difference in efficacy was observed between
the different schedules. These results demonstrate that
increased G2/M arrest does not necessarily translate into
increased clonogenic cell kill for this combination.
Sustained G2/M arrest promotes apoptotic cell death
To interrogate the possibility that prolonged G2/M arrest
following triple combination therapy would culminate in
apoptotic cell death, we used IncuCyte live cell imaging to
determine the proportion of cells expressing the apoptotic
marker Annexin V at multiple timepoints after treatments.
(See figure on previous page.)
Fig. 3 Effect of combination treatment on glycolytic and mitochondrial metabolites. UVW/NAT cells were treated with 3 Gy X-radiation, 1 mM
metformin, or 2.5 mM 2DG as single agents or in triple combination for 24 h. Cells were then harvested in solvent extraction buffer and analysed
by mass spectrometry in quadruplicate. a Principal component analysis (PCA) plot showing biological variation within the data set, which was
then used to calculate the weighted distance between each culture condition and their respective mean values ± SD. Intracellular relative
intensity of b glycolytic intermediates (including a schematic representation of the glycolytic pathway), c tricarboxylic acid (TCA) cycle
metabolites and d by-products of purine and pyrimidine metabolism. Data are means ± SD, n = 4. Treatment vs control: *p < 0.05, **p < 0.01,
***p < 0.001; treatment vs 2-DG: †††p < 0.0001 following a one-way ANOVA with Bonferroni correction
Fig. 4 The effect of combination treatment on mitochondrial respiration, glycolysis and cellular energy production. UVW/NAT cells were treated
with 3 Gy X-radiation, 1 mM metformin, or 5 mM 2DG as single agents or in combination for 24 h. Oxygen consumption rate (OCR) and
extracellular acidification rate (ECAR) of live cells were then measured using a Seahorse XFe96 Analyser, the shift in cell energy
phenotype following treatment is shown (a) The traces obtained (Supplementary Figure 6) were then used to calculate glycolytic rate (b),
minimal and maximal respiratory capacity (c) and ATP production (d)
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These data showed that 2-DG but not metformin caused
modest levels of apoptotic cell death as a single agent, with
dual drug therapy showing a supra-additive effect in UVW/
NAT cells (Fig. 6a, c). Radiation alone induced moderate
apoptosis at early timepoints but did not further enhance
efficacy of the 2-DG/metformin combination (Fig. 6b, c).
Similar results were observed using CHLA-20 cells (Supple-
mentary Fig. S9).
Discussion
Despite rigorous multi-modal treatment regimens in-
volving surgical resection, chemotherapy, radiotherapy
and immunotherapy, high-risk neuroblastoma patients
have 10-year overall survival rates of less than 40% [10,
11]. Targeted radiotherapy remains one of the most ef-
fective treatment options for high-risk disease [53], but
most patients are not cured and so there is scope to im-
prove its efficacy by using targeted drugs to overcome
treatment resistance [14].
In this study we aimed to enhance radiosensitivity by
inhibiting glycolysis, which is upregulated in cancer cells,
thus disrupting the ATP generation required to fuel their
rapid proliferation. Anticipating a compensatory increase in
mitochondrial metabolism to maintain ATP production,
we hypothesised that this could be circumvented by adding
the mitochondrial respiratory chain inhibitor metformin.
Building on recent observations in breast cancer cells [50],
we tested these hypotheses by measuring the effects of 2-
DG and metformin on the radiation responses of neuro-
blastoma and glioma cells.
Metformin failed to radiosensitise neuroblastoma (SK-
N-BE(2c)) or glioma (UVW/NAT) cells when adminis-
tered as a single agent, which is contrary to previous re-
ports [31, 32, 34]. However, we did observe that low-
dose 2-DG and metformin given in combination signifi-
cantly increased the radiosensitivity of UVW/NAT cells
but had negligible effects on SK-N-BE(2c) neuroblast-
oma cells, even when treatment was extended to 48 h.
These observations are consistent with previous reports
demonstrating a range of sensitivities to 2-DG and met-
formin combination treatment across cell lines [47–49].
Variability in response to metformin has been attributed
to genetic characteristics including p53 deficiency [47,
48], AMPKα expression [34] and MYC status [49, 54].
Resistance of SK-N-BE(2c) cells to the 2-DG/metfor-
min combination is likely to be explained by their gen-
etic background, which includes p53 mutations [55] and
amplification of the MYCN gene [56]. Amplification of
the neuronal transcription factor MYCN induces malig-
nant transformation of neuroblastoma cells and is used
for disease stratification [57], and sensitivity of neuro-
blastoma cells to impaired polyamine metabolism has
been demonstrated to correlate with extent of MYCN
amplification [54]. We therefore extended our study to
Fig. 5 The effect of 2DG and metformin on the cell cycle and alternative scheduling. a UVW/NAT cells were treated with 3 Gy X-radiation, 1 mM
metformin, or 1 mM 2-DG, as single agents or in simultaneous combination for 6 h or 24 h, and cell cycle distribution was determined following
propidium iodide staining and flow cytometric analysis. The effect of scheduling on b the cell cycle and c clonogenic survival (n = 4). Data presented
are means ± SEM from 3 independent experiments, unless otherwise stated. *p < 0.05, **p < 0.01, ***p < 0.001 compared to untreated control cells
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include CHLA-20 human neuroblastoma cells, which are
non-MYCN amplified. Since CHLA-20 cells were unable
to form clonogenic colonies, spheroid growth delay was
used as a clinically relevant readout of radiosensitivity. In
this cell line, dual treatment with 2-DG and metformin
produced significantly greater radiosensitisation than ei-
ther agent administered alone, supporting our findings in
UVW/NAT cells and consistent with data derived from
breast cancer [48, 50], prostate cancer [47] and paediatric
glioma cells [49]. Our findings support a potential role for
MYCN amplification in treatment resistance of neuro-
blastoma cells that merits further investigation.
Interrogation of the cellular metabolome by mass spec-
trometric analysis demonstrated significant disruption of
the glycolytic pathway and the electron transport chain
(ETC) following exposure to 2-DG and metformin as single
agents. We further showed that the greatest metabolite im-
balance was observed following combination of 2-DG and
metformin treatments. Even though this imbalance was not
further exacerbated by irradiation, it set the scene for
Fig. 6 The effect of combination treatment on apoptotic frequency. UVW/NAT cells were treated with 2 Gy X-radiation (administered at the start
of treatment), 1 mM metformin, or 1 mM 2DG as single agents or in combination for 48 h and were imaged every hour using the IncuCyte
Zoom imaging system. Representative images taken after 48h treatment exposure are shown (a). Apoptotic frequency was determined following
Annexin V staining. Annexin V-positive cells (displaying red fluorescence) were normalised to the total number of cells present (b) and the area
under the curve (AUC) was calculated (c) to allow comparisons between each condition and the treatment controls (untreated control (Untr Ctrl),
unstained negative control (unstained) and staurosporine positive control (SSP +ve)). Data are means ± SEM from 3 separate experiments, each
performed in sextuplet wells. *p < 0.05, **p < 0.01 compared to untreated control cells (one-way ANOVA)
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enhanced radiosensitivity. Further investigations revealed
that these large-scale metabolic imbalances ultimately cul-
minated in reduced cellular energy production. These re-
sults were corroborated by real-time analysis of oxygen
consumption rate using the Seahorse system, wherein triple
combination therapy produced a substantial shift in bio-
energetic profile from a highly energetic to a largely quies-
cent cellular phenotype. Additionally, we observed
significantly reduced ATP production, glycolytic rate, and
respiratory capacity following exposure to combination
treatments. Similar analysis of biogenetic profiles proved
useful during the characterisation of different histological
subtypes of ovarian cancer, in which highly glycolytic cell
subtypes exhibited greater susceptibility to 2-DG [58]. A
key question is how do the metabolic imbalances detailed
in this study relate to cell death following radiotherapy?
Our data support a model in which (1) metabolic shifts
from a highly energetic state to cellular quiescence prevent
proliferation and (2) increased reliance on mitochondrial
energy production following glycolytic inhibition increases
production of reactive oxygen species (ROS), which en-
hances radiation-induced ROS production, thus increasing
cytotoxicity. We hypothesise that inhibition of glycolysis by
2-DG causes a metabolic shift to oxidative phosphorylation
(OXPHOS) in order to sustain ATP production, a compen-
satory mechanism that can be circumvented by adding
metformin. Albeit by alternative methodologies, several
other studies have also demonstrated reduced ATP content
as a possible mechanism of additivity when 2-DG is com-
bined with metformin [47, 49, 50].
Of course, the radiosensitising effect of 2-DG may not be
solely due to inhibition of glycolysis. 2-DG is known to
exert off-target affects as a mannose mimetic and can cause
post-translational modifications such as N-linked glycosyla-
tion [59]. Indeed, N-linked glycosylation, in which an oligo-
saccharide is attached to a protein residue via its nitrogen
atom, is a post-translational event analogous to poly(ADP-
ribosyl)ation, whereby ADP-ribose moieties are attached to
a target protein at the site of DNA damage. We have previ-
ously demonstrated the radiosensitising properties of the
poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors ola-
parib and rucaparib in neuroblastoma and glioma cells,
where they act principally by preventing repair of radiation-
induced damage [38]. Indeed, this radiation-induced poly-
(ADP-ribosyl)ation which would consume pools of NAD+
and ADP, would occur synonymously with the ATP deple-
tion following combined 2-DG/metformin treatment. Pre-
sumably, AMP supplies would be depleted in attempts to
replenish ADP/ATP levels. This may be a possible explan-
ation as to why we observed significant reductions in abun-
dance of AMP, ADP, ATP and NAD+ following
combination therapy.
In addition to its well-documented effects on glucose me-
tabolism, we also demonstrated that 2-DG treatment had
significant effects on purine and pyrimidine metabolism. Of
note were the changes observed in ethanolamine phosphate
and hypoxanthine, which are generated by carboxylation of
serine and deamination of adenine, respectively. These me-
tabolites were significantly increased by dual and triple
combination therapies, but not by single agent treatments.
Their increased abundance may reflect attempts to repair
radiation-induced DNA damage, which require cells to in-
crease de novo purine and pyrimidine synthesis, with input
from serine and adenine, to synthesise the nucleotides re-
quired for DNA repair. Indeed, nucleotide metabolism has
been implicated in oncogene-induced cellular senescence
due to the roles of nucleotides in replication stress and the
DNA damage response [60].
Flow cytometric analysis revealed that although 2-DG
and metformin, as single agents, induced modest accumula-
tion of cells in the G2/M phase of the cell cycle, maximum
G2/M arrest was achieved by combining the two agents, as
previously shown by others [47, 48]. Our data also demon-
strated that this G2/M arrest could be further enhanced by
combination with X-irradiation and, more importantly, that
it persisted for at least 24 h after irradiation. This indicated
that optimal scheduling of therapeutic modalities could
maximise arrest in G2/M — the most radiosensitive phase
of the cell cycle. Indeed, we went on to show that schedul-
ing X-irradiation exposure 6 h before 2-DG/metformin
treatment maximised G2/M arrest. However, this treatment
schedule did not further enhance clonogenic cell kill com-
pared to the other two schedules, which is why simultan-
eous combinations were used for the rest of the study. We
predicted that the mechanism by which the 2-DG/metfor-
min combination increased radiosensitivity entailed induc-
tion of apoptosis during prolonged G2/M accumulation of
cells, as shown previously [47, 49, 50]. This hypothesis was
supported by our Incucyte data which showed the fre-
quency of Annexin V-stained UVW/NAT and CHLA-20
cells to be significantly enhanced following 2-DG/metfor-
min treatment, compared to single agent administration.
Like most other in vitro studies investigating this drug
combination [47–50], we observed cytotoxic activity of 2-
DG and metformin only at higher drug concentrations than
could be achieved clinically. In contrast, we observed potent
radiosensitising effects of the combination with lower con-
centrations (1 mM). Clinically, the recommended dose of
2-DG is 63 mg/kg/day (75 μM1), which achieved maximum
plasma concentrations in the region of 116 μg/ml (0.7 μM)
[23], although higher doses may be tolerated in combin-
ation with radiation therapy. And while metformin is not
usually given to diabetic patients at doses higher than
1500–2000 mg/day, which deliver plasma concentrations of
22-29 μM1 [27], it should be noted that shorter treatment
1Assuming 80 kg average weight and 5.15 L average circulating blood
volume.
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regimens would be required in combination with radiother-
apy, so it may be feasible to treat neuroblastoma patients
with higher daily doses. Since both drugs are already clinic-
ally approved, exhibit favourable toxicity profiles and, as far
as the authors are aware, have no documented maximum
tolerated dose to date, we consider them to be promising
therapeutic agents in combination with radiation therapy in
paediatric patients.
Conclusions
In summary, we show for the first time that the glyco-
lytic inhibitor 2-DG enhances the radiosensitivity of hu-
man neuroblastoma and glioma cells in vitro. The
radiosensitising effects of 2-DG were greatly enhanced
by combination with the antidiabetic biguanide, metfor-
min. Metabolomic analysis revealed this combination to
elicit severe disruption of key glycolytic and mitochon-
drial metabolites, causing significant reductions in ATP
generation. These results were supported by cellular bio-
energetic profiling. Combination treatment induced G2/
M arrest that persisted for at least 24 h post-irradiation,
promoting apoptotic cell death in a significant propor-
tion of cells. Our findings suggest that targeting cellular
metabolism has potential to improve clinical outcomes
by overcoming radioresistance in children with high-risk
neuroblastoma.
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